SeaStar Medical Announces First Pediatric Patient Treated In A Commercial Setting With Its FDA-Approved QUELIMMUNE Therapeutic Device
Author: Benzinga Newsdesk | July 23, 2024 08:36am
SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its U.S. Food and Drug Administration (FDA)-approved, patented cell-directed extracorporeal therapy to treat acute kidney injury (AKI) in pediatric patients weighing 10 kilograms or greater with sepsis or a septic condition requiring kidney replacement therapy (KRT). With this development, the Company has now met the August 20, 2024 FDA deadline to begin patient treatments, which is designated in the FDA's approval of QUELIMMUNE.
Posted In: ICU